vs
GLOBUS MEDICAL INC（GMED）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是RBC Bearings INC的1.8倍（$826.4M vs $461.6M），GLOBUS MEDICAL INC净利率更高（17.0% vs 14.6%，领先2.4%），GLOBUS MEDICAL INC同比增速更快（25.7% vs 17.0%），GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $99.1M），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 5.6%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
GMED vs RBC — 直观对比
营收规模更大
GMED
是对方的1.8倍
$461.6M
营收增速更快
GMED
高出8.7%
17.0%
净利率更高
GMED
高出2.4%
14.6%
自由现金流更多
GMED
多$103.3M
$99.1M
两年增速更快
GMED
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $461.6M |
| 净利润 | $140.6M | $67.4M |
| 毛利率 | 68.4% | 44.3% |
| 营业利润率 | 20.5% | 22.3% |
| 净利率 | 17.0% | 14.6% |
| 营收同比 | 25.7% | 17.0% |
| 净利润同比 | 430.4% | 16.4% |
| 每股收益（稀释后） | $1.01 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDRBC
| Q4 25 | $826.4M | $461.6M | ||
| Q3 25 | $769.0M | $455.3M | ||
| Q2 25 | $745.3M | $436.0M | ||
| Q1 25 | $598.1M | $437.7M | ||
| Q4 24 | $657.3M | $394.4M | ||
| Q3 24 | $625.7M | $397.9M | ||
| Q2 24 | $629.7M | $406.3M | ||
| Q1 24 | $606.7M | $413.7M |
净利润GMEDRBC
| Q4 25 | $140.6M | $67.4M | ||
| Q3 25 | $119.0M | $60.0M | ||
| Q2 25 | $202.8M | $68.5M | ||
| Q1 25 | $75.5M | $72.7M | ||
| Q4 24 | $26.5M | $57.9M | ||
| Q3 24 | $51.8M | $54.2M | ||
| Q2 24 | $31.8M | $61.4M | ||
| Q1 24 | $-7.1M | — |
毛利率GMEDRBC
| Q4 25 | 68.4% | 44.3% | ||
| Q3 25 | 67.2% | 44.1% | ||
| Q2 25 | 66.6% | 44.8% | ||
| Q1 25 | 67.3% | 44.2% | ||
| Q4 24 | 59.9% | 44.3% | ||
| Q3 24 | 56.8% | 43.7% | ||
| Q2 24 | 58.7% | 45.3% | ||
| Q1 24 | 60.2% | 43.1% |
营业利润率GMEDRBC
| Q4 25 | 20.5% | 22.3% | ||
| Q3 25 | 17.9% | 21.5% | ||
| Q2 25 | 10.2% | 23.2% | ||
| Q1 25 | 16.2% | 23.0% | ||
| Q4 24 | 9.2% | 21.7% | ||
| Q3 24 | 7.7% | 21.6% | ||
| Q2 24 | 7.9% | 24.0% | ||
| Q1 24 | 1.3% | 22.8% |
净利率GMEDRBC
| Q4 25 | 17.0% | 14.6% | ||
| Q3 25 | 15.5% | 13.2% | ||
| Q2 25 | 27.2% | 15.7% | ||
| Q1 25 | 12.6% | 16.6% | ||
| Q4 24 | 4.0% | 14.7% | ||
| Q3 24 | 8.3% | 13.6% | ||
| Q2 24 | 5.0% | 15.1% | ||
| Q1 24 | -1.2% | — |
每股收益（稀释后）GMEDRBC
| Q4 25 | $1.01 | $2.13 | ||
| Q3 25 | $0.88 | $1.90 | ||
| Q2 25 | $1.49 | $2.17 | ||
| Q1 25 | $0.54 | $2.33 | ||
| Q4 24 | $0.19 | $1.82 | ||
| Q3 24 | $0.38 | $1.65 | ||
| Q2 24 | $0.23 | $1.90 | ||
| Q1 24 | $-0.05 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $4.6B | $3.3B |
| 总资产 | $5.3B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资GMEDRBC
| Q4 25 | $557.2M | $107.6M | ||
| Q3 25 | $18.8M | $91.2M | ||
| Q2 25 | — | $132.9M | ||
| Q1 25 | — | $36.8M | ||
| Q4 24 | $890.1M | — | ||
| Q3 24 | $71.9M | — | ||
| Q2 24 | $82.5M | $76.8M | ||
| Q1 24 | $80.4M | $63.5M |
总债务GMEDRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益GMEDRBC
| Q4 25 | $4.6B | $3.3B | ||
| Q3 25 | $4.4B | $3.2B | ||
| Q2 25 | $4.3B | $3.1B | ||
| Q1 25 | $4.1B | $3.0B | ||
| Q4 24 | $4.2B | $2.9B | ||
| Q3 24 | $4.1B | $2.9B | ||
| Q2 24 | $4.0B | $2.8B | ||
| Q1 24 | $3.9B | $2.8B |
总资产GMEDRBC
| Q4 25 | $5.3B | $5.1B | ||
| Q3 25 | $5.1B | $5.1B | ||
| Q2 25 | $5.0B | $4.8B | ||
| Q1 25 | $4.7B | $4.7B | ||
| Q4 24 | $5.3B | $4.7B | ||
| Q3 24 | $5.1B | $4.7B | ||
| Q2 24 | $5.0B | $4.7B | ||
| Q1 24 | $4.9B | $4.7B |
负债/权益比GMEDRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $99.1M |
| 自由现金流率自由现金流/营收 | 24.5% | 21.5% |
| 资本支出强度资本支出/营收 | 5.6% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $588.8M | — |
8季度趋势，按日历期对齐
经营现金流GMEDRBC
| Q4 25 | $248.6M | $122.1M | ||
| Q3 25 | $249.7M | $88.4M | ||
| Q2 25 | $77.9M | $120.0M | ||
| Q1 25 | $177.3M | — | ||
| Q4 24 | $210.3M | $84.0M | ||
| Q3 24 | $203.7M | — | ||
| Q2 24 | $54.3M | $97.4M | ||
| Q1 24 | $52.4M | — |
自由现金流GMEDRBC
| Q4 25 | $202.4M | $99.1M | ||
| Q3 25 | $213.9M | $71.7M | ||
| Q2 25 | $31.3M | $104.3M | ||
| Q1 25 | $141.2M | — | ||
| Q4 24 | $193.2M | $73.6M | ||
| Q3 24 | $161.7M | — | ||
| Q2 24 | $26.5M | $88.4M | ||
| Q1 24 | $23.8M | — |
自由现金流率GMEDRBC
| Q4 25 | 24.5% | 21.5% | ||
| Q3 25 | 27.8% | 15.7% | ||
| Q2 25 | 4.2% | 23.9% | ||
| Q1 25 | 23.6% | — | ||
| Q4 24 | 29.4% | 18.7% | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 4.2% | 21.8% | ||
| Q1 24 | 3.9% | — |
资本支出强度GMEDRBC
| Q4 25 | 5.6% | 5.0% | ||
| Q3 25 | 4.7% | 3.7% | ||
| Q2 25 | 6.2% | 3.6% | ||
| Q1 25 | 6.0% | 3.2% | ||
| Q4 24 | 2.6% | 2.6% | ||
| Q3 24 | 6.7% | 4.1% | ||
| Q2 24 | 4.4% | 2.2% | ||
| Q1 24 | 4.7% | — |
现金转化率GMEDRBC
| Q4 25 | 1.77× | 1.81× | ||
| Q3 25 | 2.10× | 1.47× | ||
| Q2 25 | 0.38× | 1.75× | ||
| Q1 25 | 2.35× | — | ||
| Q4 24 | 7.94× | 1.45× | ||
| Q3 24 | 3.93× | — | ||
| Q2 24 | 1.71× | 1.59× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
